Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The investigators want to find out if the drugs Velcade and temsirolimus given together are
effective in treating cancer. Velcade and temsirolimus are each FDA approved individually for
certain types of cancer (Velcade for multiple myeloma and mantle cell lymphoma, and
temsirolimus for renal cell carcinoma) but are not currently approved in combination for
B-cell non-Hodgkin lymphoma. The investigators are trying to find out if giving these 2 drugs
together will improve the period of time that the patient's cancer is stopped or slowed from
growing and causing symptoms.
Phase:
Phase 2
Details
Lead Sponsor:
University of Wisconsin, Madison
Collaborators:
Millennium Pharmaceuticals, Inc. National Cancer Institute (NCI) Pfizer